Physician profile
Jason Wei
NPI 1649627753
$17,495.20
in general payments reported to CMS, 2019-2025
30 companies · $3,956 in 2025
The $3,956 reported for 2025 was more than what 93% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,930 · 2022: $4,665 · 2023: $3,936 · 2024: $3,009 · 2025: $3,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,382 · Travel and Lodging: $4,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,381.88 |
| Travel and Lodging | $4,518.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,386.52 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Boston Scientific Corporation | $4,265.35 | 2021-2025 | General - Therapies, General - Pain Management, Wavewriter Alpha Prime 16 |
| Curonix LLC | $1,107.09 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $857.08 | 2021-2025 | Xtampza, Belbuca |
| Nevro Corp. | $664.07 | 2021-2024 | Senza |
| Stimwave Technologies Incorporated | $538.47 | 2021-2022 | |
| Abbvie INC. | $340.70 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Vertos Medical, INC. | $240.73 | 2022-2024 | Mild Device Kit |
| Biohaven Pharmaceuticals, INC. | $219.36 | 2021 | |
| Spinal Simplicity, LLC | $197.93 | 2022-2025 | Ha Minuteman G3-R |
| Stryker Corporation | $184.65 | 2025 | Mild Device Kit |
| Spr Therapeutics, INC | $167.29 | 2022-2025 | Sprint Pns System |
| Tersera Therapeutics LLC | $162.97 | 2025 | Prialt |
| Averitas Pharma INC. | $155.89 | 2024-2025 | Qutenza |
| Saluda Medical Americas, INC. | $143.35 | 2024-2025 | Evoke |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.77 | 2022-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $124.17 | 2021 | |
| Sk Life Science, INC. | $123.87 | 2021 | |
| Nalu Medical, INC. | $68.22 | 2021 | |
| Protega Pharmaceutials INC | $65.93 | 2025 | Roxybond |
| Globus Medical, INC. | $65.74 | 2025 | Senza, Vyrsa V1 |
| Bioventus LLC | $63.44 | 2024 | Durolane |
| Allergan, INC. | $52.84 | 2021 | |
| Redhill Biopharma INC. | $40.37 | 2021 | |
| Ibsa Pharma INC. | $31.87 | 2021-2023 | Tirosint, Licart |
| Virtus Pharmaceuticals LLC | $27.95 | 2021 | |
| Foundation Fusion Solutions, LLC | $21.85 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.75 | 2023 | Seglentis |
| Innovation Technologies INC | $17.03 | 2025 | Irrisept |
| Valinor Pharma, LLC | $16.95 | 2024 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.